ABSTRACT
COVID-19 is still placing a heavy health and financial burden worldwide. Impairments in patient screening and risk management play a fundamental role on how governments and authorities are directing resources, planning reopening, as well as sanitary countermeasures, especially in regions where poverty is a major component in the equation. An efficient diagnostic method must be highly accurate, while having a cost-effective profile.
We combined a machine learning-based algorithm with instrumental analysis using mass spectrometry to create an expeditious platform that discriminate COVID-19 in plasma samples within minutes, while also providing tools for risk assessment, to assist healthcare professionals in patient management and decision-making. A cross-sectional study with 728 patients (369 confirmed COVID-19 and 359 controls) was enrolled from three Brazilian epicentres (São Paulo capital, São Paulo countryside and Manaus) in the months of April, May, June and July 2020.
We were able to elect and identify 21 molecules that are related to the disease’s pathophysiology and 26 features to patient’s health-related outcomes. With specificity >97% and sensitivity >83% from blinded data, this screening approach is understood as a tool with great potential for real-world application.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Sao Paulo Research Foundation (FAPESP) [2019/05718-3 to J.D., 2018/10052-1 to W.J.F., 2020/04705-2 to R.F.S., 2020/05369-6 to F.M.T.C., and 2020/04305-2 to J.C.N. and T.F.D.], Amazonas State Government, Superintendence of the Manaus Free Trade Zone (SUFRAMA), Coordination for the Improvement of Higher Education Personnel (CAPES), Department of Science and Technology (DECIT) -Brazilian Ministry of Health (MS), Ministry of Science, Technology and Innovation - National Council for Scientific and Technological Development (CNPq) [grant 403253/2020 to M.V.G.L.]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
(CAAE 32077020.6.0000.0005, CAAE 31049320.7.1001.5404 and CAAE 30299620.7.0000.0068)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data generated in this study will be anonymized to attend patient's privacy restrictions and will be available from corresponding authors upon request after publication.
